Amer Zeidan MD MBBS, MHS

Hematologic Oncology

Assistant Professor of medicine, Yale university

20 York StNew Haven, CT 06510
Phone+1 203-688-4242
Fax+1 203-688-5013

Dr. Zeidan is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zeidan's full profile Already have an account?

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Jordan Faculty of MedicineClass of 2001
Rochester Regional Health/Rochester General HospitalResidency, Internal Medicine

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CT State Medical License 2014 - 2027
MD State Medical License 2010 - 2015
NY State Medical License 2007 - 2014
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016

Clinical Trials

Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents Start of enrollment: 2017 Jun 23
COMPLETED
PHASE1
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease Start of enrollment: 2019 Jun 26
ACTIVE_NOT_RECRUITING
PHASE2
GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia Start of enrollment: 2019 Dec 06
TERMINATED
PHASE2

Publications & Presentations

PubMed

The burden of acute myeloid leukemia: an integrated review of clinical, economic, and patient-centered evidence.
Amer M Zeidan, Ruizhi Zhao, Dina Christensen, Janan Amin, Thomas W LeBlanc
Expert Review of Anticancer Therapy. 2026-08-06
Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q.
Maria Julia Montoro, Victor Navarro, Pamela Acha, Claudia Haferlach, Onyee Chan
Blood Advances. 2026-07-16
Treatment inequity among older adults with newly diagnosed acute myeloid leukemia ineligible for intensive therapy.
Alain Mina, Yanqing Xu, Tatyana A Kapustyan, Mazaher Dhalla, Cheng Chen
Leukemia & Lymphoma. 2026-07-12

Lectures

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
New Therapies for Better Patient Outcomes in Acute Myeloid Leukemia: Integration of Recent Data Sets Into Clinical Practice
60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

EHA 2026 AML Highlights: What New Combinations Mean for SurvivalJune 26th, 2026
Inside Information: Faron to Advance Bexmarilimab into a Registrational Phase 2/3 Study in Treatment-Naïve (Frontline) HR-MDS After Positive Meeting with the FDAAugust 18th, 2025
Is AML Harder to Treat After Relapse?March 6th, 2020